Coya Therapeutics Awaits FDA Decision on ALS Treatment as Q2 Results Show Mixed Performance
Key Insights
Coya Therapeutics is awaiting FDA decision on its IND application for COYA 302, a dual immunomodulatory therapy targeting ALS (search), with a decision anticipated by the end of August.
The company reported $29.8 million in cash reserves but saw collaboration revenues drop significantly from $3.4 million to $0.2 million in Q2 2025.
COYA 302 combines low-dose interleukin-2 and CTLA-4 Ig (search) to enhance regulatory T cell function and suppress inflammation in neurodegenerative diseases (search).
Coya Therapeutics is positioned at a critical juncture as the biotechnology company awaits FDA clearance for its lead ALS (search) treatment while navigating mixed second-quarter financial results. The Houston-based clinical-stage company reported having $29.8 million in cash and cash equivalents as of June 30, 2025, providing runway for its regulatory T cell-focused therapeutic programs.
FDA Decision Pending for Lead ALS Program
The company's Chief Medical Officer Dr. Fred Grossman stated, "We look forward to the FDA's decision on our IND submission for COYA 302 in ALS (search), which represents a significant milestone for our lead program. Pending clearance, we are prepared to initiate our controlled Phase 2 clinical trial in ALS."
CEO Arun Swaminathan noted that the FDA decision is "anticipated by the end of August," representing a key near-term catalyst for the company. However, the FDA has been unable to meet the original review goal date for Coya's investigational new drug application for the phase 2 ALS (search) study.
COYA 302's Dual Mechanism Approach
COYA 302 represents an investigational biologic combination therapy designed with a dual immunomodulatory mechanism of action. The treatment comprises proprietary low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig (search), intended to enhance the anti-inflammatory function of regulatory T cells (search) (Tregs (search)) while suppressing inflammation produced by activated monocytes (search) and macrophages (search). The therapy is being developed for subcutaneous administration, with these mechanisms potentially having additive or synergistic effects.
The company's therapeutic approach targets dysfunctional Tregs (search), which underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress, resulting in lack of homeostasis of the immune system.
Financial Performance Shows Revenue Decline
Coya's second-quarter financial results revealed significant revenue fluctuations. Collaboration revenues dropped to $0.2 million for the three months ended June 30, 2025, compared to $3.4 million for the same period in 2024, representing a decrease of approximately $3.3 million. The decline was primarily attributed to the immediate recognition of license revenue upon executing the First Amendment to the DRL Development Agreement during the prior year quarter.
Research and development expenses decreased to $3.7 million from $4.6 million year-over-year, a reduction of approximately $0.9 million. This decrease was primarily due to a $1.2 million reduction in preclinical expenses related to COYA 302 in ALS (search) work, partially offset by increases in internal research and development expenses and sponsored research.
General and administrative expenses increased to $2.9 million from $2.1 million in the prior year, driven by higher stock-based compensation, professional services, and investor relations expenses. The company reported a net loss of $6.1 million for the quarter, compared to a $2.9 million net loss in the same period of 2024.
Expanding Pipeline and Future Plans
Beyond ALS (search), Coya plans to submit an IND for frontotemporal dementia (search) (FTD (search)) by the end of the year, expanding its neurodegenerative disease portfolio. The company is also developing COYA 303 (search), an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist (search) (GLP-1 RA) designed for subcutaneous administration.
In preclinical studies, COYA 303 (search) demonstrated a dual immunomodulatory mechanism resulting in additive or synergistic anti-inflammatory effects, which the company attributes to increased Treg function and suppressed pro-inflammatory myeloid cells and responder T cells.
Financing and Strategic Positioning
To support its operations and clinical development programs, Coya has filed a $75 million mixed shelf offering that includes both common stock and warrants. This financing vehicle provides the company with flexibility to access capital markets as needed for its advancing clinical programs.
Swaminathan expressed confidence in the company's approach, stating, "We are encouraged by the growing body of data supporting our regulatory T cell enhancement approach, including the recent findings from the investigator-initiated trial in FTD (search) and promising pre-clinical results with COYA 303 (search). These advances strengthen our confidence in the potential of COYA 302 in neurodegenerative diseases (search) like ALS (search) and FTD."